Literature DB >> 27993997

Letter: Vedolizumab in Pregnancy.

Juliette Sheridan1, Garret Cullen1, Glen Doherty1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27993997     DOI: 10.1093/ecco-jcc/jjw214

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  3 in total

Review 1.  Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.

Authors:  Javier P Gisbert; María Chaparro
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

2.  Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review.

Authors:  Birgit Terjung; Renate Schmelz; Robert Ehehalt; Jochen Klaus; Jana Knop; Sabine Schwind; Thomas Wilke; Andreas Stallmach
Journal:  Therap Adv Gastroenterol       Date:  2020-10-16       Impact factor: 4.409

3.  Evaluation of the Developmental Toxicity of Vedolizumab, an α4β7 Receptor Antagonist, in Rabbit and Nonhuman Primate.

Authors:  David Crawford; Mitchell Friedman
Journal:  Int J Toxicol       Date:  2019-07-31       Impact factor: 2.032

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.